Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
| Autor: | Sara Rundquist, Olof Grip, Per Karlén, Linda Nilsson, Scott Montgomery, Hans Strid, Henrik Hjortswang, Susanna Jäghult, Leif Angelison, Jonas Halfvarson, Jan Björk, Carl Eriksson |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Clinical effectiveness Population Disease Inflammatory bowel disease Medication Adherence Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Crohn Disease Internal medicine medicine Humans Registries 030212 general & internal medicine education Proportional Hazards Models Sweden education.field_of_study Crohn's disease Tumor Necrosis Factor-alpha business.industry Remission Induction Gastroenterology Antibodies Monoclonal Middle Aged medicine.disease Golimumab Treatment Outcome Female 030211 gastroenterology & hepatology Observational study business medicine.drug |
| Zdroj: | Scandinavian Journal of Gastroenterology. 53:1257-1263 |
| ISSN: | 1502-7708 0036-5521 |
| Popis: | The effectiveness of golimumab in Crohn's disease (CD) is largely unknown as it is not approved for the treatment of the disease. We aimed to identify the population of CD patients treated with golimumab in Sweden, to assess the effectiveness of golimumab (defined as the drug retention rate), and to identify predictors of drug discontinuation.Patients with CD who received at least one injection of golimumab were identified through the Swedish National Quality Registry for Inflammatory Bowel Disease, which includes prospectively collected clinical information. Cox regression models were used to identify predictors of golimumab discontinuation.The study cohort involved 94 patients of whom the majority (96.8%) had previously discontinued at least one anti-tumour necrosis factor (anti-TNF) agent. The drug retention rate at 12 weeks was 85.1%. Predictors of golimumab discontinuation at 12 weeks were previous surgery (adjusted HR = 7.52, 95% CI: 1.12-50.36), concomitant corticosteroid use at baseline (adjusted HR = 5.70, 95% CI: 1.13-28.68) and female sex (adjusted HR = 6.59; 95% CI: 1.04-41.62). The median duration of follow-up was 89 (IQR: 32-158) weeks. The drug retention at the most recent follow-up was 35.1%. Predictors of golimumab discontinuation at the most recent follow-up were corticosteroid use at baseline (adjusted HR = 2.60, 95% CI: 1.17-5.79) and female sex (adjusted HR = 2.24; 95% CI: 1.19-4.23).Patients with CD treated with golimumab were a treatment-refractory group. Despite this, more than one-third of the patients appeared to have had clinical benefit after a median follow-up of more than 1.5 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|